News

Acesion Pharma Commences Phase 1 Study in Atrial Fibrillation

COPENHAGEN, Denmark— 12 March 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces it has commenced the clinical study for its lead compound AP30663. Acesion is developing a portfolio of drugs addressing both paroxysmal (acute) and persistent AF.

Link to Press Release